Research
Hormonal
Circulating soluble DPP4 (sDPP4) acts as an adipokine that contributes to vascular dysfunction and cardiovascular disease risk in obese and diabetic individuals.
In people with obesity and type 2 diabetes, higher levels of a specific form of the DPP4 enzyme found in the blood are linked to an increased risk of heart and blood vessel problems. Managing blood sugar may help mitigate these risks.
ModerateSupportsMEDIUM confidence
Circulating, soluble DPP4 has been identified as a new adipokine, which exerts both para- and endocrine effects... data are accumulating that the adipokine-related effects of DPP4 may play an important role in the pathogenesis of cardiovascular disease.
Why this rating
The paper states 'data are accumulating,' suggesting emerging but not yet definitive clinical consensus compared to the primary indication.
Source
DPP4 in diabetes
Diana Röhrborn · Frontiers in Immunology · 2015
DOI 10.3389/fimmu.2015.00386
narrative_reviewCited 434×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- DPP4 inhibitors (gliptins) treat type 2 diabetes by blocking the enzymatic degradation of incretin hormones (GLP-1 and GIP), thereby prolonging their half-life and enhancing glucose-dependent insulin secretion.Good
- DPP4 inhibitors exert effects beyond incretin regulation by interacting with non-incretin substrates such as SDF-1, NPY, PYY, and Substance P, potentially influencing inflammation, angiogenesis, and appetite.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →